

**Review**

**Pg. 0445-0452**

**One year in review 2021: pathogenesis of rheumatoid arthritis**

D. Testa, S. Calvacchi, F. Petrelli, D. Giannini, S. Bilia, A. Alunno, I. Puxeddu

**Rapid paper**

**Pg. 0453-0455**

**Efficacy and safety of switching Jak inhibitors in rheumatoid arthritis: an observational study**

M. Retuerto, E. Trujillo, C. Valero, C. Fernandez-Espartero, C.Y. Soleto, A. Garcia-Valle, E. Aurrecoechea, M. Garijo, A. Lopez, J. Loricera, J.L. Pablos

**Full Papers**

**Pg. 0456-0462**

**Receptor activator of nuclear factor kappa-B ligand (RANKL) serum levels are associated with progression to seropositive/negative rheumatoid arthritis**

A.N. Burska, J.J. El-Jawhari, J. Wu, R.J. Wakefield, H. Marzo-Ortega, P.G. Conaghan, P. Emery, F. Ponchel, J.E. Freeston

**Pg. 0463-0470**

**Toenail abnormalities in rheumatoid arthritis patients are associated with radiographic damage and impact disability: a cross sectional study nested within a cohort**

G. Sánchez-Cárdenas, I. Contreras-Yáñez, S. Méndez-Flores, J. Merayo-Chalico, A. Barrera-Vargas, J. Domínguez-Cherit, V. Pascual-Ramos

**Pg. 0471-0478**

**Semiquantitative analysis of sacroiliac joint to sacrum ratio of bone scintigraphy to predict spinal progression in early axial spondyloarthritis: a pilot study**

H.K. Min, H.-R. Kim, Y. So, H.W. Chung, S.-H. Lee

**Pg. 0479-0486**

**The effect of methotrexate on neutrophil reactive oxygen species and CD177 expression in rheumatoid arthritis**

U. Kaundal, A. Khullar, B. Leishangthem, S. Jain, A. Dhooria, B. Saikia, V. Dhir

**Pg. 0487-0493**

**Absolute reduction of peripheral regulatory T cell in patients with relapsing polychondritis**

F.-Y. Hu, J. Wang, S.-X. Zhang, R. Su, N. Yan, C. Gao, X.-F. Li, C.-H. Wang

**Pg. 0494-0500**

**Phagocytosis and inflammation in crystal-induced arthritis: a synovial fluid and in vitro study**

C. Baggio, P. Sfriso, A. Cignarella, P. Galozzi, A. Scanu, F. Mastrotto, M. Favero, R. Ramonda, F. Oliviero

**Pg. 0501-0507**

**Cardiovascular events and change in cholesterol levels in patients with rheumatoid arthritis treated with tocilizumab: data from the REGATE Registry**

C. Lukas, M. Redondin, I. Pane, M. Soubrier, E. Houvenagel, J. Sibilia, B. Combe, J. Morel

**Pg. 0508-0518**

**Novel classification of axial spondyloarthritis to predict radiographic progression using machine learning**

Y.B. Joo, I.-W. Baek, K.-S. Park, I. Tagkopoulos, K.-J. Kim

**Pg. 0519-0524**

**The indirect immunofluorescence assay autoantibody profiles of myositis patients without known myositis-specific autoantibodies**

M. Casal-Dominguez, I. Pinal-Fernandez, K. Pak, A. Marin-Sanchez, M.T. Sanz-Martinez, A. Baucells, Y. Hosono, L. Christopher-Stine, A.L. Mammen  
for the Johns Hopkins Myositis Center Group

**Pg. 0525-0531**

**Effectiveness and safety of baricitinib in rheumatoid arthritis: a monocentric, longitudinal, real-life experience**

F.R. Spinelli, F. Ceccarelli, C. Garufi, I. Duca, S. Mancuso, E. Cipriano, E. Dell'unto, C. Alessandri, M. Di Franco, C. Perricone, R. Priori, V. Ricciari, R. Scrivo, A. Sili Scavalli, S. Truglia, G. Valesini, F. Conti

**Pg. 0532-0536**

**Disease characteristics of psoriatic arthritis patients may differ according to age at psoriasis onset: cross-sectional data from the Psoriatic Arthritis-International Database**

E. Bilgin, S.Z. Aydin, I. Tinazzi, Ö. Bayindir, G. Kimyon, C. Özişler, A. Doğru, E. Dalkiliç, K. Aksu, G. Yildirim Çetin, S. Yilmaz, D. Solmaz, A. Omma, M. Can, O. Küçükşahin, Ş. Yavuz, E.D. Ersözlü, L. Kiliç, E.F. Tarhan, M. Aydin Tufan, L. Akyol, M. Çinar, A. Erden, E. Gönüllü, F. Yildiz, S. Bakirci, F. Erbasan, S. Ergülü Eşmen, A. Küçük, A. Tufan, A. Balkarli, R. Mercan, Ş. Erten, S. Akar, T. Kaşifoğlu, T. Duruöz, V. Yazisiz, U. Kalyoncu

**Pg. 0537-0545**

**Real-life persistence of golimumab in patients with chronic inflammatory rheumatic diseases: results of the 2-year observational GO-PRACTICE study**

R.-M. Flipo, F. Tubach, P. Goupille, E. Lespessailles, N. Harid, S. Sequeira, P. Bertin, B. Fautrel

**Pg. 0546-0554**

**Prevalence of hepatitis B virus infection and risk of reactivation in rheumatic population undergoing biological therapy**

M.C. Ditto, S. Parisi, V. Varisco, R. Talotta, A. Batticciotto, M. Antivalle, M.C. Gerardi, M. Agosti, R. Borrelli, E. Fusaro, P. Sarzi-Puttini

**Pg. 0555-0563**

**Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients?**

L. Riancho-Zarrabeitia, V.M. Martínez-Taboada, I. Rúa-Figueroa, F. Alonso, M. Galindo-Izquierdo, J. Ovalles, A. Olivé-Marqués, N. Mena Vázquez, J. Calvo-Alén, R. Menor Almagro, E. Tomero Muriel, E. Uriarte Isacelaya, A. Boteanu, M. Andres, M. Freire González, G. Santos Soler, M.E. Ruiz-Lucea, M. Ibáñez-Barceló, I. Castellví, C. Galisteo, V. Quevedo Vila, E. Raya, J. Narváez, L. Expósito, J.A. Hernández Beriaín, L. Horcada, E. Aurrecochea, J.M. Pego Reigosa

**Pg. 0564-0569**

**Seasonal onset of polymyalgia rheumatica: correlations with the pattern of clinical presentation, disease severity and outcome in 383 patients from a single centre**

A. Sobrero, S. Paolino, E. Hysa, D. Camellino, V. Tomatis, M. Cutolo, M.A. Cimmino

**Pg. 0570-0577**

**Mass-spectrometric identification of carbamylated proteins present in the joints of rheumatoid arthritis patients and controls**

M.K. Verheul, G.M. Janssen, A. De Ru, G. Stoeken-Rijsbergen, E.N. Levarht, J.C. Kwekkeboom, N. Bomer, A. Ioan-Facsinay, I. Meulenbelt, R.A. Cordfunke, J.W. Drijfhout, R.E. Toes, P.A. Van Veelen, L.A. Trouw

**Pg. 0578-0586**

**Atherosclerosis in rheumatoid arthritis: associations between anti-cytomegalovirus IgG antibodies, CD4+CD28null T-cells, CD8+CD28null T-cells and intima-media thickness**

B. Wahlin, A.E. Fasth, K. Karp, K. Lejon, V. Malmström, A. Rahbar, S. Wållberg-Jonsson, A. Södergren

**Pg. 0587-0600**

**Tissue factor and human apolipoprotein H genetic variants and pro-inflammatory cytokines in systemic lupus erythematosus patients**

A. Wajda, A. Sowińska, E. Haładyj, B. Stypińska, J. Nałęcz-Janik, P.P. Jagodziński, D. Majewski, M. Olesińska, A. Paradowska-Gorycka

**Pg. 0601-0605**

**Prevalence and outcome of thrombocytopenia in systemic lupus erythematosus: single-centre cohort analysis**

T. Costa Pires, R. Caparrós-Ruiz, P. Gaspar, D.A. Isenberg

**Pg. 0606-0611**

**Up-regulation of autophagy by etanercept treatment results in TNF-induced apoptosis reduction in EA.hy926 endothelial cell line**

C. Barbati, T. Colasanti, M. Vomero, F. Ceccarelli, A.I. Celia, C. Perricone, F.R. Spinelli, F. Conti, G. Valesini, C. Alessandri

**Pg. 0612-0620**

**Immune-related adverse events in patients with solid-organ tumours treated with immunotherapy: a 3-year study of 102 cases from a single centre**

I. Gonzalez-Mazón, L. Sánchez-Bilbao, J.L. Martín-Varillas, A. García-Castaño, M. Delgado-Ruiz, I. Bernat Piña, J.L. Hernández, S. Castañeda, J. Llorca, M.A. González-Gay, R. Blanco

**Pg. 0621-0630**

**Painless and painful synovitis have similar ultrasound and clinical outcomes: one-year cohort study in longstanding rheumatoid arthritis women patients**

D.F. Pereira, J. Natour, L.H. Ribeiro, F.B. Ferreira, A.R. Fernandes, R.N. Furtado

**Pg. 0631-0638**

**COVID-19 shares clinical features with anti-melanoma differentiation-associated protein 5 positive dermatomyositis and adult Still's disease**

Y. Kondo, Y. Kaneko, H. Takei, H. Tamai, H. Kabata, T. Suhara, R. Yamamoto, H. Nagata, M. Ishii, J. Sasaki, N. Hasegawa, K. Fukunaga, T. Takeuchi  
for the Keio Donner Project

**Pg. 0639-0647**

**Do patients with rheumatoid arthritis show a different course of COVID-19 compared to patients with spondyloarthritis?**

R. Hasseli, A. Pfeil, B.F. Hoyer, A. Krause, H.-M. Lorenz, J.G. Richter, T. Schmeiser, R.E. Voll, H. Schulze-Koops, C. Specker, U. Müller-Ladner

**Brief Paper**

**Pg. 0648-0650**

**Rituximab hypersensitivity reactions and tolerance of ofatumumab therapy**

S.B. Ali, C. Yuson, P. Hissaria

**Review**

**Pg. 0651-0659**

**Epilepsy in systemic lupus erythematosus**

E.A. Grasso, M. Cacciatore, C. Gentile, L. Breda, R. Giacomelli, A. Verrotti

**Pg. 0660-0667**

**Incidence of spondyloarthritis and its subtypes: a systematic review**

Y. Alamanos, E. Pelechas, P.V. Voulgari, A.A. Drosos

**Pg. 0668-0675**

**JAK/STAT pathway and nociceptive cytokine signalling in rheumatoid arthritis and psoriatic arthritis**

N. Crispino, F. Ciccia

**Pg. 0676-0687**

**SARS-CoV-2 infection in patients with systemic autoimmune diseases**

P. Brito-Zerón, A. Sisó-Almirall, A. Flores-Chavez, S. Retamozo, M. Ramos-Casals

**Paediatric Rheumatology**

**Pg. 0688-0694**

**Validation of the EULAR/ACR 2017 idiopathic inflammatory myopathy classification criteria in juvenile dermatomyositis patients**

E. Sag, S. Demir, Y. Bilginer, B. Talim, G. Haliloglu, S. Ozen

**Letter**

**Pg. 0695**

**Use of rituximab in a multicentre cohort of patients with rheumatic diseases during the outbreak of novel SARS-COV-2 infection**

A. Batticciotto, D. Marotto, V. Giorgi, P. Balzarini, E.G. Favalli, S. Balduzzi, M. Fredi, C. Bazzani, S. Sartorelli, V. Ravagnani, S. Tamanini, L. Castelnovo, A.M. Lurati, S. Farah, S. Bongiovanni, R. Caporali, L. Dagna, P. Faggioli, F. Franceschini, C.M. Montecucco, F. Salaffi, M. Galli, A. Cappelli, P. Sarzi-Puttini

**Pg. 0696**

**Changing the traditional p-value significance threshold to .005 does not decrease the number of statistically significant p-values in observational studies more than in randomised controlled trials**

M. Oztas, Z.T. Dincer, N. Sut, H. Yazici

**Pg. 0697-0699**

**Biological drugs in paediatric COVID-19 infection: what patients, which drug, how much and how long**

M.V. Mastrolia, I. Maccora, E. Marrani, I. Pagnini, G. Simonini

**Pg. 0700**

**Sustained remission of ankylosing spondylitis following intravesical Bacillus Calmette et Guérin immunotherapy for bladder cancer**

E. Toussirot, G. Guichard, P. Saas

**Pg. 0701-0702**

**Novel treatment strategy of polymyalgia rheumatica targeting drug-free remission**

T. Hosoya, T. Sugihara, N. Miyasaka, S. Yasuda

**Pg. 0703**

**High prevalence of small intestinal bacterial overgrowth (SIBO) in spondylarthropathy**

J.-M. Laroche, N. Kapel, N. Benahmed, P. Claudepierre, X. Chevalier, L. Barbot-Trystram

**Pg. 0704**

**Resolution of Schnitzler's syndrome after haematopoietic stem cell transplantation**

A. Paladini, A. Vitale, B. Frediani, L. Cantarini